Literature DB >> 1933896

Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line.

J Foley1, S L Cohn, H R Salwen, D Chagnovich, J Cowan, K L Mason, L M Parysek.   

Abstract

Neuroblastomas are malignant childhood neoplasms that arise from derivatives of the neural crest. We report the characterization of a new neuroblastoma cell line, designated NBL-W, derived from the primary tumor of a patient with stage IVS disease (S. L. Cohn, C. V. Herst, H. S. Maurer, and S. T. Rosen, J. Clin. Oncol., 5: 1441-1444, 1987) according to the criteria of Evans [A. E. Evans, G. J. D'Angio, and J. Randolf, Cancer (Phila.), 27: 374-378, 1971]. Neurite-bearing (N) and substrate-adherent (S) cell lines have been subcloned from the parent line. N and S cells can interconvert, and both cell types label with the neural crest cell surface marker antibody, HNK-1. Cells in the subcloned lines and in the parent line have been shown by Southern blot analysis to contain approximately 100 copies of the N-myc gene. Cytogenetic analysis shows a homogeneously staining region present on chromosome 19. Although these subclones are of identical genotype, the S cells express lower amounts of N-myc mRNA and protein as compared to the N cells. N cells express several neuronal proteins including the neurotransmitter-processing enzymes tyrosine hydroxylase and dopamine beta-hydroxylase, the neuronal intermediate filament proteins peripherin and NF66/alpha-internexin, and the neural cell adhesion molecule. S cells generally lack neuronal markers but express the mesenchymal intermediate filament protein vimentin, and a small subset of the S cells express glial fibrillary acidic protein. Some S cells were labeled weakly with neural cell adhesion molecule antibody; others were negative. S cells did not express the glial marker S-100 or a melanocyte marker, tyrosinase. Thus, S cells express the neural crest marker HNK-1 but do not express a set of antigens characteristic of any known cell type derived from the neural crest. These results are consistent with the suggestion that differential N-myc expression may be involved in the interconversion of N and S cells but indicate that the S cell phenotype need not represent a highly differentiated neural crest derivative.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933896

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma.

Authors:  R Amitay; D Nass; D Meitar; I Goldberg; B Davidson; L Trakhtenbrot; F Brok-Simoni; A Ben-Ze'ev; G Rechavi; Y Kaufmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Intron 1 is required for cell type-specific, but not injury-responsive, peripherin gene expression.

Authors:  Thomas E Uveges; Yuqing Shan; Bridget E Kramer; David C Wight; Linda M Parysek
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

3.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

4.  Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Authors:  Alexandre Chlenski; Chanyoung Park; Marija Dobratic; Helen R Salwen; Brian Budke; Jae-Hyun Park; Ryan Miller; Mark A Applebaum; Emma Wilkinson; Yusuke Nakamura; Philip P Connell; Susan L Cohn
Journal:  Mol Cancer Ther       Date:  2019-01-23       Impact factor: 6.261

5.  Notch pathway activation induces neuroblastoma tumor cell growth arrest.

Authors:  Peter E Zage; Riitta Nolo; Wendy Fang; John Stewart; Guillermo Garcia-Manero; Patrick A Zweidler-McKay
Journal:  Pediatr Blood Cancer       Date:  2011-07-08       Impact factor: 3.167

6.  UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Authors:  Peter E Zage; Natalie Sirisaengtaksin; Yin Liu; Monica Gireud; Brandon S Brown; Shana Palla; Kristen N Richards; Dennis P M Hughes; Andrew J Bean
Journal:  Cancer       Date:  2012-09-18       Impact factor: 6.860

7.  Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.

Authors:  Kristen N Richards; Patrick A Zweidler-McKay; Nadine Van Roy; Frank Speleman; Jesus Trevino; Peter E Zage; Dennis P M Hughes
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

8.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Authors:  Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

9.  RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.

Authors:  Reza Rahbari; Mio Kitano; Lisa Zhang; Swaroop Bommareddi; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

10.  PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma.

Authors:  Nilay Shah; Jianjun Wang; Julia Selich-Anderson; Garrett Graham; Hasan Siddiqui; Xin Li; Javed Khan; Jeffrey Toretsky
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.